Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.96 |
| ▸ | BLM | P54132 | 6/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.96 |
| ▸ | MAPT | P10636 | 5/20 | 0.96 |
| ▸ | RECQL | P46063 | 4/20 | 0.96 |
| ▸ | APEX1 | P27695 | 4/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.96 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norepinephrine SCHEMBL31352030 | 1.00 | BLM (0.96) | BLMTDP1KDM4EMAPTRECQL | |
| L-Norepinephrine SCHEMBL317206 | 1.00 | BLM (0.96) | BLMTDP1KDM4EMAPTRECQL | |
| L-Norepinephrine SCHEMBL31281490 | 1.00 | BLM (0.96) | BLMTDP1KDM4EMAPTRECQL | |
| L-Norepinephrine SCHEMBL29180591 | 0.98 | BLM (0.92) | BLMTDP1KDM4EMAPTRECQL | |
| Norepinephrine SCHEMBL2429869 | 0.98 | TDP1 (1.00) | BLMTDP1KDM4EMAPTRECQL | |
| L-Norepinephrine SCHEMBL29460319 | 0.98 | TDP1 (1.00) | BLMTDP1KDM4EMAPTRECQL | |
| L-Norepinephrine SCHEMBL29371849 | 0.98 | TDP1 (1.00) | BLMTDP1KDM4EMAPTRECQL | |
| Norepinephrine SCHEMBL2609 | 0.98 | TDP1 (1.00) | BLMTDP1KDM4EMAPTRECQL | |
| L-Norepinephrine SCHEMBL3489077 | 0.98 | TDP1 (1.00) | BLMTDP1KDM4EMAPTRECQL | |
| Norepinephrine SCHEMBL29399946 | 0.98 | TDP1 (1.00) | BLMTDP1KDM4EMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037640-A | Organic-inorganic composite metal anti-corrosion pigment and preparation method thereof | 华东理工大学 | 2026-05-15 | — | — | CN | claimed |
| CN-119822976-A | Demethyl bitartrate preparation method of epinephrine | 海南卓科制药有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-119707710-A | Norepinephrine external Process for preparing racemate | 蚌埠丰原医药科技发展有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119707720-A | Preparation method of norepinephrine hydrochloride | 蚌埠丰原医药科技发展有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4470566-A1 | ROOM TEMPERATURE STABLE FORMULATION OF NOREPINEPHRINE | B. Braun Melsungen AG (DE) | 2024-12-04 | — | — | EP | claimed |
| CN-119040983-A | Ultrafast preparation method and application of metal organic framework film based on additive | 天津大学 | 2024-11-29 | — | — | CN | claimed |
| CN-116041194-B | Synthesis method of norepinephrine hydrochloride | 武汉武药制药有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-117100901-A | Photoinitiated biological tissue adhesive, gel sheet, preparation method and application | 艾弈医疗科技(上海)有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-115672702-B | Decorative board and processing technology thereof | 青岛美中建材机械有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-115634821-B | Coating method of household decorative plate | 深圳市华剑建设集团股份有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-111019981-A | Method for synthesizing R-noradrenaline by asymmetric method | 蚌埠丰原医药科技发展有限公司 | 2020-04-17 | — | — | CN | claimed |
| US-20150126556-A1 | Treatment of Skin and Mucosal Superficial Wounds Using Adrenergic Receptor Agonists | BARRY JILIN 2021 LIVING TRUST | 2015-05-07 | — | — | US | claimed |
| US-8969331-B2 | Treatment of skin and mucosal superficial wounds using adrenergic receptor agonists | BARRY JILIN 2021 LIVING TRUST | 2015-03-03 | — | — | US | claimed |
| CN-103524569-A | Technological method for removing glucose in isomaltooligosaccharide product by using multiple immobilized enzymes | UNIV HEBEI TECHNOLOGY | 2014-01-22 | — | — | CN | claimed |
| WO-2010039827-A2 | TREATMENT OF SKIN AND MUCOSAL SUPERFICIAL WOUNDS USING ADRENERGIC RECEPTOR AGONISTS | KELNER ROMAN (US) | 2010-04-08 | — | — | WO | claimed |
| US-20100081721-A1 | TREATMENT OF SKIN AND MUCOSAL SUPERFICIAL WOUNDS USING ADRENERGIC RECEPTOR AGONISTS | BARRY JILIN 2021 LIVING TRUST | 2010-04-01 | — | — | US | claimed |
| US-6303588-B1 | APPLYING TO PORTIONS OF THE SKIN OF SUCH PATIENT WHICH HAVE ABNORMAL SKIN CELL METABOLISM BIOACTIVE AGENT COMPRISING ADENOSINE-5-TRIPHOSPHATE, QUANOSINE-5-TRIPHOSPHATE AND PHOSPHINOSITEDES AND BIOLOGICALLY ACCEPTABLE CARRIER | Danielov, Michael M. | 2001-10-16 | — | — | US | claimed |
| US-5885974-A | DECREASES THE DOSAGE OF BIOACTIVE AGENT NECESSARY, WHEN ADMINISTERED TO A PATIENT WITH ABNORMAL CELL METABOLISM, TO CORRECT THE ABNORMAL CELL METABOLISM AND PROMOTE THE RESUMPTION OF NORMAL CELL METABOLISM | Danielov, Michael M. (US) | 1999-03-23 | — | — | US | claimed |
| WO-1996017621-A1 | CORRECTING BIOLOGICAL INFORMATION TRANSFER USING THREE BIOLOGICAL INFORMATION BLOCKS | DNS SCIENTIFIC, INC. (US) | 1996-06-13 | — | — | WO | claimed |
| US-4275074-A | Catecholamine treatment of ocular hypertension | Dobbie, Graham J. (US) | 1981-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081721-A1 | TREATMENT OF SKIN AND MUCOSAL SUPERFICIAL WOUNDS USING ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRA2A 3/4885 |
| US-20150126556-A1 | Treatment of Skin and Mucosal Superficial Wounds Using Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.